Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.78 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.78 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.78 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.78 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL28246596 | 0.97 | OPRD1 (0.81) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL3476234 | 0.97 | OPRD1 (0.75) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL22234325 | 0.97 | OPRD1 (0.75) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL30301300 | 0.94 | OPRD1 (0.85) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL6650502 | 0.92 | OPRD1 (0.69) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL6650507 | 0.92 | OPRD1 (0.69) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL16635671 | 0.92 | OPRD1 (0.85) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL29223948 | 0.91 | OPRD1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL15055206 | 0.89 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL149700 | 0.89 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281680-A1 | DRUG-ELUTING SURGICAL ARTICLES AND RELATED METHODS | BIOSAPIEN INC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250177290-A1 | DRUG-ELUTING SURGICAL ARTICLES AND METHODS OF USE THEREOF | BioSapien Inc. | 2025-06-05 | — | — | US | disclosed |
| EP-4522238-A2 | DRUG-ELUTING SURGICAL ARTICLES AND METHODS OF USE THEREOF | Biosapien Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119546355-A | Drug eluting surgical article and method of use | 生物智慧公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-3899995-B1 | DRUG-ELUTING SURGICAL ARTICLES AND RELATED METHODS | BIOSAPIEN INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-11969527-B2 | Drug-eluting biomaterials and related methods | BioSapien Inc. (US) | 2024-04-30 | — | — | US | disclosed |
| EP-3597262-B1 | FORMULATION FOR INTRACUTANEOUS INJECTION | XERIS PHARMACEUTICALS INC (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2023220400-A2 | DRUG-ELUTING SURGICAL ARTICLES AND METHODS OF USE THEREOF | BioSapien Inc. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-114588124-B | Delayed release pharmaceutical composition | 江苏恒瑞医药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-113632188-B | Drug eluting surgical articles and related methods | 生物智慧公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20050112201-A1 | Delayed release dosage forms | PENWEST PHARMACEUTICALS CO. (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2005027843-A2 | CHRONOTHERAPEUTIC DOSAGE FORMS | PENWEST PHARMACEUTICALS CO. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005027878-A1 | DELAYED RELEASED DOSAGE FORMS | PENWEST PHARMACEUTICALS CO. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004093850-A1 | TABLET WITH COLOURED CORE | JAGOTEC AG (CH) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093843-A1 | DELAYED RELEASE TABLET WITH DEFINED CORE GEOMETRY | JAGOTEC AG (CH) | 2004-11-04 | — | — | WO | disclosed |
| CN-1499960-A | Chornotherapeutic dosage forms | ����˹��ҩ�﹫˾ | 2004-05-26 | — | — | CN | disclosed |
| US-20030082230-A1 | Chronotherapeutic dosage forms and methods of treatment using chronotherapy | PENWEST PHARMACEUTICALS COMPANY | 2003-05-01 | — | — | US | disclosed |
| US-5378474-A | Pellet having a core including at least one highly soluble active ingredient and a coating partially soluble at high acidity; opiod drugs | F. H. FAULDING & CO. LIMITED (AU) | 1995-01-03 | — | — | US | disclosed |
| US-5330766-A | Water soluble active ingredient core coated with matrix and enteric polymers; high speed, uniform release | F. H. FAULDING & CO. LIMITED (AU) | 1994-07-19 | — | — | US | disclosed |
| US-5202128-A | Oral administering | F. H. FAULDING & CO. LIMITED (AU) | 1993-04-13 | — | — | US | disclosed |